Liver disease biotech Vital Therapies files for a $86 million IPO

By Renaissance Capital,

Shutterstock photo

Vital Therapies, a clincal-stage biotech developing treatments for acute liver failure, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol VTL. Vital Therapies initially filed confidentially on July 22, 2013. Credit Suisse and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by